Literature DB >> 22306913

High-risk prostate cancer: is androgen deprivation monotherapy still appropriate?

Vahakn B Shahinian1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22306913      PMCID： PMC3720172          DOI： 10.1038/aja.2011.182

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  15 in total

1.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

Authors:  Miljenko V Pilepich; Kathryn Winter; Colleen A Lawton; Robert E Krisch; Harvey B Wolkov; Benjamin Movsas; Eugen B Hug; Sucha O Asbell; David Grignon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

Review 2.  Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies.

Authors:  Liv Veldeman; Indira Madani; Frank Hulstaert; Gert De Meerleer; Marc Mareel; Wilfried De Neve
Journal:  Lancet Oncol       Date:  2008-04       Impact factor: 41.316

3.  Three-dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture.

Authors:  Sean P Elliott; Stephanie L Jarosek; Shaheen R Alanee; Badrinath R Konety; Kathryn E Dusenbery; Beth A Virnig
Journal:  Cancer       Date:  2011-03-16       Impact factor: 6.860

Review 4.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

Authors:  D Andrew Loblaw; Katherine S Virgo; Robert Nam; Mark R Somerfield; Edgar Ben-Josef; David S Mendelson; Richard Middleton; Stewart A Sharp; Thomas J Smith; James Talcott; Maryellen Taplin; Nicholas J Vogelzang; James L Wade; Charles L Bennett; Howard I Scher
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

5.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

Authors:  Anthony L Zietman; Michelle L DeSilvio; Jerry D Slater; Carl J Rossi; Daniel W Miller; Judith A Adams; William U Shipley
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

6.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.

Authors:  J T Wei; R L Dunn; M S Litwin; H M Sandler; M G Sanda
Journal:  Urology       Date:  2000-12-20       Impact factor: 2.649

7.  Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.

Authors:  Matthew R Cooperberg; Andrew J Vickers; Jeanette M Broering; Peter R Carroll
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

8.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

9.  High-risk prostate cancer in the United States, 1990-2007.

Authors:  Matthew R Cooperberg; Janet Cowan; Jeannette M Broering; Peter R Carroll
Journal:  World J Urol       Date:  2008-03-28       Impact factor: 4.226

10.  Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party--Subgroup on Prostatic Cancer.

Authors:  G J Fellows; P B Clark; L L Beynon; J Boreham; C Keen; M C Parkinson; R Peto; J N Webb
Journal:  Br J Urol       Date:  1992-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.